COMPUGEN news, videos and press releases - Page 7
For more news please use our advanced search feature.
COMPUGEN - More news...
COMPUGEN - More news...
- Compugen Second Quarter 2019 Conference Call Scheduled for Monday, August 5, 2019 at 8:30 AM ET
- Compugen Expands Intellectual Property Portfolio for COM701 with New U.S. Patent Covering Combination Use with anti-PD-1 Antibody
- Compugen Appoints Eran Perry to Its Board of Directors
- Compugen Presents Update on COM701 Phase 1 Trial at the 2019 ASCO Annual Meeting
- Compugen to Present at the Jefferies 2019 Healthcare Conference
- Compugen Reports First Quarter 2019 Results
- Compugen Doses First Patient in COM701/Opdivo® (Nivolumab) Combination Arm of Phase 1 Study in Patients With Advanced Solid Tumors
- Compugen First Quarter 2019 Conference Call Scheduled for Monday, May 20, 2019 at 8:30 AM ET
- Compugen Presents Update on COM701 Phase 1 Trial at the 2019 AACR Annual Meeting
- Compugen Announces Purchase of Company Shares by its Board of Directors and Members of Management
- Compugen Announces Issuance of Two U.S. Composition of Matter Patents for COM701, Its Lead Immuno-Oncology Product Candidate
- Compugen to Present at the Cowen and Company 39th Annual Health Care Conference
- Compugen Presents Update on COM701 Phase 1 Trial at ASCO-SITC Clinical Immuno-Oncology Symposium
- Compugen Reports Fourth Quarter and Full Year 2018 Results and Announces Corporate Restructuring to Streamline Operations
- Compugen Fourth Quarter and Full Year 2018 Conference Call Scheduled for Tuesday, February 26, 2019 at 8:30 AM ET
- Compugen Announces Publication of Two Peer-Reviewed Papers Demonstrating the Role of PVRIG as a Novel Immune Checkpoint for Cancer Immunotherapy
- Compugen's Phase 1 Trial of COM701 Featured as a Trial-in-Progress at The ASCO-SITC Clinical Immuno-Oncology Symposium
- Compugen Announces Issuance of U.S. Patent for COM902, Its TIGIT Antibody Product Candidate for Cancer Immunotherapy
- Compugen Reports Third Quarter 2018 Results
- Compugen Third Quarter 2018 Conference Call Scheduled for Wednesday, November 7, 2018 at 8:30 AM ET
- Compugen Announces First Patient Dosed with COM701, a First-in-Class Cancer Immunotherapy Antibody, in Phase 1 Clinical Trial
- Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors
- Compugen Reports Second Quarter 2018 Results
- Compugen Second Quarter 2018 Conference Call Scheduled for Wednesday, August 1, 2018 at 8:30 AM ET
- Compugen Announces FDA Clearance of IND Application for COM701, a First-in-class Immuno-Oncology Therapeutic Antibody
- Compugen Announces $21 Million Registered Direct Offering of Ordinary Shares and Warrants
- Compugen Announces the Appointment of New Board Members
- Compugen Reports First Quarter 2018 Results
- Compugen First Quarter 2018 Conference Call Scheduled for Wednesday, May 9, 2018 at 10:00 AM ET
- Compugen Reports on Status of Investigational New Drug Application for COM701, a First-in-Class Immuno-Oncology Therapeutic Antibody
